GoodRx
GoodRx is a digital healthcare platform that offers prescription drug price comparison, discount coupons, and telehealth services. The company works with pharmacy benefit managers to negotiate discounted prices at over 70,000 pharmacies, generating revenue through referral fees paid by PBMs when consumers use GoodRx discount codes.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-10-02. Score revised 2026-10-02: 49 → 46.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
GoodRx was founded in 2011 by Doug Hirsch, Trevor Bezdek and Scott Marlette and launched a free price-comparison website and iPhone app in February 2012. Revenue came from fees PBMs shared when a GoodRx code was used, economics users could not see. Francisco Partners and Spectrum Equity took a majority stake in 2015, but the record shows no documented harms to users before 2017.
The $9.99-a-month Gold subscription launched in May 2017, and from 2017 GoodRx sent users' medication and health-condition data to Facebook, Google, Criteo and others through pixels and SDKs while its privacy policy promised never to share health information with advertisers. In August 2019 it uploaded lists of users who had bought specific medications to Facebook for ad targeting. Silver Lake invested at a $2.8 billion valuation in 2018, and GoodRx bought telehealth company HeyDoctor in 2019.
A Consumer Reports investigation on February 25, 2020 found GoodRx sending medication data to more than 20 companies; within days GoodRx stopped sending prescription data to Facebook, added data-deletion and tracking opt-outs and appointed a privacy executive. The September 2020 IPO raised about $1.14 billion at a $12.7 billion valuation and installed a dual-class structure. Amazon Pharmacy's entry and Drug Channels' critique of GoodRx's spread-based fees framed the period, while the HealthiNation purchase added health video content for drugmakers.
Shares fell 39% on March 1, 2022 after a weak forecast. In May a grocery chain identified by analysts as Kroger stopped accepting most PBM discounts on a subset of drugs, removing GoodRx prices at stores that produced almost a quarter of its prescription revenue, and in August GoodRx cut about 140 jobs (16%). In November it became Express Scripts' exclusive discount-card partner, paying the PBM a marketing fee, its first step toward embedding its pricing inside PBM benefits.
The FTC's first Health Breach Notification Rule case brought a $1.5 million penalty and a 20-year order banning health-data sharing for advertising. The co-founder co-CEOs stepped down in April 2023, and GoodRx pricing was built into CVS Caremark's Cost Saver and MedImpact's program, live from January 2024, which pharmacies later said cut their reimbursements. GoodRx spent about $104 million on buybacks in 2023 despite a net loss and $160 million in 2024, much of it buying shares from its pre-IPO private equity owners.
Independent pharmacies sued from October 30, 2024, alleging the integrated savings program was price fixing; NCPA joined and the cases became MDL No. 3148. Under CEO Wendy Barnes (from January 2025) GoodRx bought back $217.4 million of stock in 2025, let independents opt out of the program, and pivoted toward drugmaker-funded pricing and subscriptions, launching weight-loss plans and the $14.99-a-month Companion and making subscriptions the main call to action on its homepage and price pages. Monthly active consumers fell from 6.6 million in Q4 2024 to 5 million in Q2 2026.
Alternatives
Nonprofit drug discount database that finds patient assistance programs, state pharmaceutical programs, and discount cards without monetizing your health data. Particularly useful for brand-name drugs where Cost Plus Drugs and discount cards provide less savings. Free to use with no account required.
Mark Cuban's online pharmacy sells generics at disclosed cost plus a 15% markup and a $5 pharmacy fee (plus shipping), with no PBM middleman and no health data advertising. Directly addresses GoodRx's core problems. Easy switch for generic medications: search your drug, get the price, fill online or at select partner pharmacies. Does not carry all medications and requires a valid prescription.
Free prescription savings card with no subscription required and no documented history of sharing health data with advertisers, unlike GoodRx. Works at about 35,000 pharmacies. Easy switch: search your drug, show the card at the pharmacy. Prices are competitive with GoodRx and sometimes lower. Owned by RxSense, a pharmacy benefits technology company.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (48 events)
GoodRx Founded by Former Facebook Executives
Doug Hirsch (former VP of Product at Facebook), Trevor Bezdek, and Scott Marlette (one of Facebook's first 20 employees) founded GoodRx in Santa Monica, California. The platform was created to address prescription drug price opacity by aggregating discount prices across pharmacies.
GoodRx Launches Price Comparison with Opaque PBM Fee Structure
GoodRx announced its prescription drug price comparison tool, available as a website and free iPhone app, with a database of over one million prices for more than 6,000 brand-name and generic drugs. While the service gave consumers price transparency, its revenue model (fees shared by pharmacy benefit managers when a GoodRx coupon is used) was not visible to users, who could not see the economics behind the displayed prices.
Francisco Partners and Spectrum Equity Acquire Majority Stake
Private equity firms Francisco Partners and Spectrum Equity acquired a majority stake in GoodRx in 2015. The PE investment introduced institutional growth pressure and monetization expectations, shifting the company from an angel-funded startup to a PE-backed growth vehicle.
GoodRx Gold Subscription Plan Launched
GoodRx launched its Gold membership in May 2017 at $9.99 per month (covering up to six family members, with a free first month), promising prices up to 50% lower than free GoodRx. The subscription added a recurring revenue stream alongside PBM referral fees; later user reviews complained that Gold sometimes offered no more savings than the free tier.
GoodRx Begins Sharing Health Data with Facebook via Tracking Pixels
According to the FTC complaint, in 2017 GoodRx configured a Facebook tracking pixel on its GoodRx and GoodRx Gold websites and used SDKs that shared users' medication and health-condition information and identifiers with Facebook, Google, Criteo and others; pixel-based ad campaigns targeting users who viewed specific drugs ran from August 2017. Between at least October 2017 and March 2019 its privacy policy stated: 'we never provide advertisers or any other third parties any information that reveals a personal health condition or personal health information.'
Silver Lake Invests at $2.8 Billion Valuation
Silver Lake made a strategic growth investment in GoodRx, taking about a third of the company in equity at a $2.8 billion valuation. The investment joined existing PE backers Francisco Partners and Spectrum Equity, further concentrating private equity ownership and growth expectations ahead of a planned IPO.
Kroger Rx Savings Club Launched Powered by GoodRx
GoodRx partnered with Kroger to launch the Kroger Rx Savings Club, a paid membership ($36 a year for individuals, $72 for families) built on GoodRx's pricing technology, offering free and low-cost tiers on common generics. By early 2022 GoodRx disclosed that this grocer represented less than 5% of its network pharmacies but almost a quarter of its prescription transactions revenue, a concentration that became visible when the chain stopped accepting many PBM discounts.
GoodRx Uploads User Medication Data to Facebook for Ad Targeting
In August 2019, GoodRx compiled lists of users who had purchased specific medications including heart disease and blood pressure drugs, uploading their email addresses, phone numbers, and mobile advertising IDs to Facebook for targeted advertising campaigns. This was among the most egregious instances of health data monetization documented by the FTC.
GoodRx Acquires Telehealth Company HeyDoctor
GoodRx acquired HeyDoctor, a telemedicine company, and rebranded it as GoodRx Care. The acquisition expanded GoodRx beyond prescription discounts into virtual healthcare visits, adding a telehealth revenue stream but also expanding the surface area for health data collection and monetization.
Consumer Reports Finds GoodRx Sending Medication Data to 20+ Companies
A Consumer Reports investigation found GoodRx's website and app sending personal details to more than 20 internet companies; Google, Facebook and marketing firm Braze received the names of medications users researched along with identifiers that could pinpoint their devices. The FTC later said that until this public revelation GoodRx had no sufficient written privacy or data-sharing policies in place.
GoodRx Stops Sending Prescription Data to Facebook After Exposé
Following the Consumer Reports investigation, GoodRx stopped sending users' prescription data to Facebook, added controls to delete data and opt out of cookies and third-party tracking (extending CCPA-style rights nationwide), appointed a vice president of data privacy and said it had audited its third-party agreements. In retesting, Consumer Reports saw no data going to Facebook.
Drug Channels Exposes How GoodRx Profits from Broken Pricing System
Drug Channels published an analysis showing how GoodRx profits from the opaque PBM spread-pricing system without negotiating directly with pharmacies. GoodRx collects referral fees from PBMs each time a consumer uses a discount code, effectively profiting as a middleman in a system that already squeezes independent pharmacies on reimbursement rates.
GoodRx IPO Raises $1.1 Billion at $12.7 Billion Valuation
GoodRx went public on the NASDAQ at $33 per share, above the expected $24-$28 range, raising about $1.14 billion at a valuation of roughly $12.7 billion; shares closed the first day at $50.50. Its dual-class structure gives Class B shares, held by the co-founders and the pre-IPO private equity backers, ten votes each; as of April 2024 Class B carried about 96.8% of total voting power.
Amazon Pharmacy Launch Threatens GoodRx's Core Business
Amazon launched Amazon Pharmacy with Prime member discounts, directly competing with GoodRx for uninsured and underinsured consumers. GoodRx stock dropped over 20% on the news. Amazon's entry marked the first serious competitive threat from a major tech company to GoodRx's discount card model.
GoodRx Acquires HealthiNation for $75 Million
GoodRx agreed to buy HealthiNation, a health video content producer, for $75 million in cash. HealthiNation joined GoodRx's manufacturer solutions business, giving pharmaceutical manufacturers new ways to reach audiences through health content and deepening the advertising monetization model.
GoodRx Stock Crashes 39% on Weak Revenue Forecast
GoodRx shares plunged 39% after the company reported Q4 2021 revenue of $213.3 million, slightly below estimates, and forecast 2022 growth of about 23% (roughly $917 million) versus analyst expectations of $963 million. The stock, which peaked at $64.22 shortly after the 2020 IPO, fell below $16.73, about 50% below its IPO-day opening.
GoodRx Acquires vitaCare for $150 Million
GoodRx completed the acquisition of vitaCare Prescription Services for $150 million from TherapeuticsMD. vitaCare's tech platform helped patients navigate brand medication access and adherence, expanding GoodRx's pharma manufacturer solutions offerings. The business was later deprioritized during the 2023 restructuring.
Grocery Chain (Reportedly Kroger) Stops Accepting Many GoodRx Discounts
GoodRx disclosed that an unnamed grocery chain, identified by analysts as Kroger, had taken actions affecting acceptance of discounts from most PBMs for a subset of drugs, so many GoodRx prices became unavailable at its stores at once. GoodRx said the grocer was less than 5% of its network pharmacies but almost a quarter of Q1 2022 prescription transactions revenue, expected about $30 million of lost Q2 revenue, and the stock fell 23%.
GoodRx Lays Off 140 Employees, 16% of Workforce
GoodRx laid off approximately 140 employees, representing 16% of its workforce, primarily in technology and marketing groups. The company expected $23-$25 million in annualized cash savings. Glassdoor reviews described the layoff process as poorly handled, with employees learning of termination in a Zoom meeting where cameras, microphones, and chat were disabled.
GoodRx Becomes Express Scripts' Exclusive Discount Card Partner
GoodRx announced it would become the exclusive partner in Express Scripts' Price Assure program from 2023, integrating its prices into the PBM's commercial benefit for generics. Drug Channels reported that GoodRx would earn an admin fee when members used a lower cash price and would pay Express Scripts a marketing fee for acquiring consumers, noting that discount cards are a form of spread pricing funded by per-prescription fees on pharmacies.
FTC Imposes $1.5 Million Fine for Health Data Sharing Violations
The FTC announced its first-ever enforcement action under the Health Breach Notification Rule against GoodRx, imposing a $1.5 million civil penalty. The FTC found GoodRx shared sensitive health information including prescription medications, health conditions, and personal identifiers with Facebook, Google, and Criteo for advertising since at least 2017, while falsely displaying a HIPAA compliance seal. GoodRx was permanently barred from sharing health data for advertising and placed under 20 years of government scrutiny.
Judge Approves FTC Settlement with 20-Year Oversight
A federal judge approved the FTC's $1.5 million settlement with GoodRx, formalizing the permanent ban on sharing health data for advertising and establishing 20 years of government oversight. The settlement required GoodRx to obtain affirmative express consent before disclosing health information to any third party and to implement a comprehensive privacy program.
Co-Founders Step Down as Co-CEOs
Trevor Bezdek and Doug Hirsch stepped down as co-CEOs of GoodRx. Scott Wagner, former GoDaddy CEO, was appointed interim CEO. Bezdek became chairman of the board while Hirsch took on the role of chief mission officer.
CVS Caremark and GoodRx Announce Caremark Cost Saver
CVS Caremark and GoodRx announced Caremark Cost Saver, under which eligible Caremark members automatically get GoodRx's price on many generic drugs at in-network pharmacies when it is lower than the plan price, starting January 1, 2024. The program became one of the integrated savings programs that independent pharmacies later alleged suppressed their reimbursements.
GoodRx and MedImpact Announce Integrated Savings Program
GoodRx and PBM MedImpact announced a program, live for members from January 1, 2024, that automatically compares a member's benefit price with GoodRx's price and applies the lower one, with GoodRx's price-comparison technology integrated into MedImpact's platform. GoodRx already had similar integrations with CVS Caremark and Express Scripts. Independent pharmacies later alleged these integrated savings programs let PBMs suppress reimbursement rates using competitively sensitive data shared through GoodRx.
Rite Aid Bankruptcy Impacts GoodRx Pharmacy Network
Rite Aid filed for Chapter 11 bankruptcy protection on October 15, 2023, when it operated more than 2,100 stores, and later closed many locations before liquidating after a second bankruptcy in 2025. In its Q2 2025 results GoodRx said the Rite Aid bankruptcy, together with volume reduction in one of its integrated savings programs, would cost about $35-$40 million of 2025 revenue.
GoodRx Strikes $13 Million Side Settlement, Draws Show-Cause Order
While the consolidated privacy class action was pending in California, GoodRx agreed a $13.0 million settlement with a separate group of plaintiffs in the Southern District of Florida on behalf of a nationwide class that included the California class. The California plaintiffs objected, and Judge Araceli Martinez-Olguin ordered GoodRx to show cause why it should not be sanctioned for failing to notify her court of the Florida case; the Florida suit was later voluntarily dismissed.
GoodRx Repurchases $77.8 Million in Stock During Q4 2023
GoodRx repurchased $77.8 million worth of Class A common stock (approximately 14.1 million shares) during Q4 2023 under its share repurchase program. This represented a significant capital allocation to buybacks while the company posted a net loss for full year 2023, prioritizing stock price support over reinvestment.
GoodRx Board Approves $450 Million Stock Buyback Program
GoodRx's board authorized a new $450 million stock repurchase program with no expiration date, after the prior program expired on February 23, 2024. The authorization came days after GoodRx reported a 2023 net loss of $8.9 million.
GoodRx Buys $151.4 Million of Stock From Its Private Equity Owners
GoodRx repurchased 20.9 million shares from Francisco Partners and Spectrum Equity at $7.19 each, a discount to the market price, for $151.4 million. It followed a $65.9 million repurchase from Spectrum in November 2023; total buybacks were about $104 million in 2023, when GoodRx posted a net loss, and $160 million in 2024.
GoodRx Shifts to Direct Pharmacy Contracting Model
A GoodRx guest post on Drug Channels described a shift in contracting: alongside its traditional multi-PBM network (70,000+ pharmacies), GoodRx began contracting directly with retail pharmacies such as Walgreens and CVS through hybrid, full-direct and single-source PBM models. Direct deals priced on acquisition cost tie participating pharmacies more closely to GoodRx's own pricing.
Independent Pharmacies File First Price-Fixing Lawsuit Against GoodRx
Independent pharmacies filed at least three class actions in late October and early November 2024, starting with Keaveny Drug's suit on October 30, against GoodRx and, in most cases, PBMs CVS Caremark, Express Scripts, MedImpact and Navitus, alleging the integrated savings program amounts to Sherman Act price fixing. The suits claim GoodRx aggregates competitively sensitive PBM reimbursement data so PBMs need not compete on pharmacy payments; Keaveny's suit estimates pharmacies could be underpaid about $35 million in 2024 alone.
GoodRx Agrees to $25 Million Class Action Data Sharing Settlement
GoodRx agreed to pay $25 million to settle the consolidated consumer class action over sharing health data with Meta, Google and Criteo through tracking tools; the deal covered GoodRx only. Judge Araceli Martinez-Olguin declined to approve it after a June 2025 hearing, and on January 16, 2026 denied preliminary approval of a revised $32 million settlement (adding Criteo), finding the parties had 'largely failed to address the Court's previously-identified concerns.'
GoodRx Appoints Wendy Barnes as CEO, Ending Interim Leadership
GoodRx appointed healthcare industry veteran Wendy Barnes as president and CEO effective January 1, 2025, replacing interim CEO Scott Wagner. Barnes was CEO of RxBenefits and previously president of PBM Express Scripts, with earlier roles at Rite Aid and Pfizer.
NCPA Joins Price-Fixing Class Action Against GoodRx
The National Community Pharmacists Association (NCPA), representing nearly 19,000 independent pharmacies, joined the Community Care Rx class action against GoodRx and PBMs. NCPA CEO B. Douglas Hoey stated that GoodRx's model 'preferentially lists some large chain pharmacies in their search results despite the higher-ranked pharmacies having higher prices, excluding nearly all independent pharmacies from appearing in the results.'
GoodRx Sues to Strike Down Arkansas Discount Card Law
GoodRx filed a federal lawsuit in Little Rock arguing that parts of Arkansas's statute regulating health discount cards, which requires cards to state that the discounts are not insurance and that consumers may cancel within 30 days, violate the First and Fourteenth Amendments. The suit came after a private foundation sued GoodRx in state court alleging its cards did not comply.
Price-Fixing Cases Consolidated into MDL in Rhode Island
The Judicial Panel on Multidistrict Litigation consolidated all GoodRx pharmacy price-fixing lawsuits into MDL No. 3148 in the District of Rhode Island, titled In Re: GoodRx and Pharmacy Benefit Manager Antitrust Litigation (No. II). The consolidation signaled the growing scale and seriousness of the antitrust allegations.
Community Link Lets Independent Pharmacies Opt Out of Integrated Savings
GoodRx launched Community Link, offering independent pharmacies direct contracts with cost-plus pricing anchored on NADAC and no PBM involvement. From July 1, 2025 all independent pharmacies were opted out of GoodRx's integrated savings program by default, with the option to opt in after signing a direct contract; signing does not waive a pharmacy's right to join litigation against GoodRx.
Judge Keeps Meta and Google in GoodRx Data Sharing Lawsuit
Judge Araceli Martinez-Olguin denied Meta, Google and Criteo's motion to dismiss the consolidated consumer class action over GoodRx's sharing of health data through tracking tools, finding the claims sufficiently pleaded and that disclosures in GoodRx's and Meta's terms did not establish consent; two California medical-privacy claims were dismissed.
Arkansas Attorney General Settles Discount Card Claims by Consent Judgment
The Arkansas attorney general sued GoodRx on September 24, 2025 alleging the same discount-card disclosure violations as the private Mullens Foundation suit plus deceptive trade practices; the next day a county court entered a consent judgment releasing GoodRx from those claims for cards distributed since 2022 in exchange for an immaterial payment. In July 2026 the attorney general moved to intervene to seek dismissal of the private suit.
GoodRx Launches Weight-Loss Telehealth Subscription
GoodRx launched GoodRx for Weight Loss, a telehealth subscription for FDA-approved GLP-1 treatment at an introductory $39 a month through January 2026 and $119 from February 1, 2026, with medication billed separately; with Novo Nordisk it offered first-time users Ozempic and Wegovy at $199 a month for the first two fills of the lowest doses, then $349.
GoodRx Gold Price Protection Feature Discontinued
GoodRx discontinued its Gold Price Protection feature effective December 31, 2025; prices members had locked in under the program expired that day and no longer applied. The removal cut a benefit of the $9.99/month Gold subscription.
TrumpRx Launches Using GoodRx Technology
The federal TrumpRx website launched, displaying manufacturers' cash prices for certain drugs using technology from GoodRx, which its annual report describes as a key integration partner for drugmakers offering discounted cash prices on the site. In May 2026 the White House added more than 600 generic drugs to TrumpRx through Cost Plus Drugs, Amazon Pharmacy and GoodRx.
GoodRx Spent $217.4 Million on Buybacks in 2025
GoodRx reported 2025 revenue of $796.9 million and net income of $30.4 million, and said it repurchased 48.9 million shares for $217.4 million during the year, including $84.9 million paid in March 2025 to Francisco Partners, the founders' Idea Men and Spectrum. Monthly active consumers fell from 6.6 million in Q4 2024 to 5.3 million in Q4 2025, and subscription revenue fell 3%.
GoodRx CEO Paid $23.4 Million in 2025
GoodRx's proxy statement reported 2025 total compensation of $23,367,483 for CEO Wendy Barnes, mostly new-hire stock and option awards plus a $2 million retention bonus, against median employee pay of $263,977, a ratio of 88.5 to 1. The company had 697 employees at the end of 2025.
GoodRx Launches $14.99-a-Month Companion Subscription
GoodRx launched GoodRx Companion at $14.99 a month, offering more than 200 free generic medications, hundreds more under $10, $19 online care visits and discounts on dental, vision, lab and imaging services. Management later said Companion was now its primary subscription, though Gold was not being discontinued, and a family plan followed in September 2026 at $24.99 a month.
GoodRx Makes Subscriptions Its Primary Call to Action
On its Q2 2026 call GoodRx said it is shifting product and marketing investment to subscriptions and making them the primary call to action across its homepage and price pages, and that some transactions will move from free coupons to subscriptions. Prescription transactions revenue fell 26% and monthly active consumers fell 12% to about 5 million, while Pharma Direct revenue rose 76%.
Judge Preliminarily Approves $32 Million GoodRx Privacy Settlement
On the third attempt, a federal judge in California preliminarily approved the $32 million settlement by GoodRx and Criteo of the consumer class action over tracking tools that sent users' health information to Meta, Google and Criteo, provisionally certifying a class of people who used GoodRx before April 20, 2024. Meta and Google are not part of the settlement.
Evidence (49 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (7 entries)
49→46. D1 5→4 (correction: fact audit showed the MAC drop is attributed to store closures and ISP volume, not user flight; core free tool intact), D3 4→5 (event: $217.4M buybacks in 2025 vs $30.4M net income and $121M product spend, much of 2023-25 buybacks paid to PE insiders), D6 6→4 (recalibration: deceptive data sharing ended 2020 and is under the 2023 FTC order; current patterns are subscription CTAs, teaser pricing, short refund window), D10 6→5 (recalibration: posture under the FTC order is compliant; aggressive tactics (2023 side settlement, 2025 Arkansas challenge) fit 4-5, exposure alone is not posture). Since Feb 2026: FY2025 buybacks $217.4M, TrumpRx launch on GoodRx tech, Companion subscription (May 2026) and subscriptions made primary CTA, MACs to ~5M, privacy settlement preliminarily approved Sept 2026, pharmacy MDL motion to dismiss briefed. Eras: Startup Origins kept; 'PE-Backed Monetization' re-dated 2017-06-01→2017-05-20 (Gold launch) and relabeled 'Gold and Covert Tracking'; 'IPO & Health Data Trade' re-dated 2020-10-01→2020-02-25 (Consumer Reports exposé), relabeled 'Exposé and IPO Boom', and split at 2022-03-01 (stock crash) into new 'Stock Crash Retrenchment'; 'FTC Enforcement & Layoffs' re-dated 2023-03-01→2023-02-01 and relabeled 'FTC Order, PBM Integration'; current era re-dated 2026-02-15 (assessment date)→2024-10-30 (first pharmacy suit) and relabeled 'Lawsuits and Subscription Pivot'. Trajectory worsening→stable (mixed: subscription upsell and buybacks vs ISP opt-out for independents and privacy settlement progress). D4 evidence strengthened with the FY2025 annual report and GoodRx's data-deletion page. SingleCare alternative: 'selling'→'sharing' health data.
Checked 75 items (32 timeline, 35 evidence, 5 milestones, 3 alternatives) + prose. 36 verified, 30 corrected (8 date-only), 8 re-sourced, 1 removed. Invented/contradicted: Gold launch price $5.99 (Pharmacy Near Me 2017: $9.99); Gold Price Protection 'lower of Gold or free price' (GoodRx support: price lock); Rite Aid '2,300+' stores (Axios: 2,100+); SingleCare 'backed by RedCard' (SingleCare: RxSense); Kroger MAU '5% drop 6.4M to 6.1M' (10-Q: 3% YoY decline); MACs '5.3 million' (Q2 2025 release: 5.7M); $25M settlement 'resolved' claims (ClassAction.org: rejected); '20 competitors' (SEO listicle only). Also fixed 96.8% voting attribution, FTC order date (Feb 2023), settlement/ruling dates, MDL date, Marlette board claim.
Removed typed-in site scores from alternatives text (they go stale on re-score; the page shows live scores). No other changes.
Added 1 missing dimension narrative